Recombinant Human CCNB2 Protein，His

CCNB2, or Cyclin B2, is a crucial regulatory protein involved in the control of the cell cycle, particularly during the transition from the G2 phase to mitosis. As a member of the cyclin family, CCNB2 partners with cyclin-dependent kinases (CDKs), specifically CDK1, to form a complex that drives the phosphorylation of target proteins, thereby promoting the progression of cell division. Research has shown that aberrations in CCNB2 expression and activity are associated with various cancers, suggesting its potential role as a biomarker for tumorigenesis and disease progression. The need for CCNB2-derived recombinant proteins arises from their potential applications in understanding cell cycle dynamics and developing targeted therapies. The production of these proteins enables detailed studies into their structure-function relationships, interactions with other cell-cycle regulators, and contributions to oncogenic processes. Furthermore, recombinant CCNB2 can facilitate high-throughput screening of novel compounds that may modulate its activity, paving the way for therapeutic innovations in cancer treatment. In recent years, advancements in protein engineering and expression systems have enhanced the yield and functionality of recombinant CCNB2, making it a valuable tool for both basic and applied research in oncology. The ongoing investigations into CCNB2's roles necessitate a comprehensive understanding of its biochemical properties and interactions, underscoring the importance of topical research involving its recombinant forms. Thus, the exploration of recombinant CCNB2 not only enriches our comprehension of cell cycle regulation but also offers promising avenues for clinical applications in cancer therapy.